Gene therapy for lower urinary tract dysfunction

Naoki Yoshimura, Minoru Miyazato, Katsumi Sasaki, Hitoshi Yokoyama, Tomohiko Oguchi, Michael B. Chancellor, Yasuhito Funahashi

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Lower urinary tract dysfunction is caused by functional and pathophysiological alterations of the peripheral organs, including the urothelium and detrusor smooth muscle, as well as peripheral and central nervous systems. Recent research in this field has increased our understanding of the mechanisms of lower urinary tract dysfunction, and new drugs have been developed, leading to increased treatment options and changing medical care for lower urinary tract symptoms. Nevertheless, clinicians still often experience refractory and treatment-resistant cases against conventional therapeutic modalities. For such cases, gene therapy targeting for the lower urinary tract and its afferent pathway is anticipated to offer a new therapeutic approach. Therefore, in this article, we review the possibility and current status of gene therapy for lower urinary tract dysfunction.

Original languageEnglish
Pages (from-to)56-63
Number of pages8
JournalInternational Journal of Urology
Volume20
Issue number1
DOIs
Publication statusPublished - Jan 2013
Externally publishedYes

Fingerprint

Urinary Tract
Genetic Therapy
Afferent Pathways
Urothelium
Lower Urinary Tract Symptoms
Gene Targeting
Peripheral Nervous System
Therapeutics
Smooth Muscle
Central Nervous System
Research
Pharmaceutical Preparations

Keywords

  • Bladder pain
  • Gene therapy
  • Lower urinary tract dysfunction
  • Overactive bladder

ASJC Scopus subject areas

  • Urology

Cite this

Yoshimura, N., Miyazato, M., Sasaki, K., Yokoyama, H., Oguchi, T., Chancellor, M. B., & Funahashi, Y. (2013). Gene therapy for lower urinary tract dysfunction. International Journal of Urology, 20(1), 56-63. https://doi.org/10.1111/j.1442-2042.2012.03226.x

Gene therapy for lower urinary tract dysfunction. / Yoshimura, Naoki; Miyazato, Minoru; Sasaki, Katsumi; Yokoyama, Hitoshi; Oguchi, Tomohiko; Chancellor, Michael B.; Funahashi, Yasuhito.

In: International Journal of Urology, Vol. 20, No. 1, 01.2013, p. 56-63.

Research output: Contribution to journalArticle

Yoshimura, N, Miyazato, M, Sasaki, K, Yokoyama, H, Oguchi, T, Chancellor, MB & Funahashi, Y 2013, 'Gene therapy for lower urinary tract dysfunction', International Journal of Urology, vol. 20, no. 1, pp. 56-63. https://doi.org/10.1111/j.1442-2042.2012.03226.x
Yoshimura N, Miyazato M, Sasaki K, Yokoyama H, Oguchi T, Chancellor MB et al. Gene therapy for lower urinary tract dysfunction. International Journal of Urology. 2013 Jan;20(1):56-63. https://doi.org/10.1111/j.1442-2042.2012.03226.x
Yoshimura, Naoki ; Miyazato, Minoru ; Sasaki, Katsumi ; Yokoyama, Hitoshi ; Oguchi, Tomohiko ; Chancellor, Michael B. ; Funahashi, Yasuhito. / Gene therapy for lower urinary tract dysfunction. In: International Journal of Urology. 2013 ; Vol. 20, No. 1. pp. 56-63.
@article{d925c7a9fc0c4268b6b879368724021f,
title = "Gene therapy for lower urinary tract dysfunction",
abstract = "Lower urinary tract dysfunction is caused by functional and pathophysiological alterations of the peripheral organs, including the urothelium and detrusor smooth muscle, as well as peripheral and central nervous systems. Recent research in this field has increased our understanding of the mechanisms of lower urinary tract dysfunction, and new drugs have been developed, leading to increased treatment options and changing medical care for lower urinary tract symptoms. Nevertheless, clinicians still often experience refractory and treatment-resistant cases against conventional therapeutic modalities. For such cases, gene therapy targeting for the lower urinary tract and its afferent pathway is anticipated to offer a new therapeutic approach. Therefore, in this article, we review the possibility and current status of gene therapy for lower urinary tract dysfunction.",
keywords = "Bladder pain, Gene therapy, Lower urinary tract dysfunction, Overactive bladder",
author = "Naoki Yoshimura and Minoru Miyazato and Katsumi Sasaki and Hitoshi Yokoyama and Tomohiko Oguchi and Chancellor, {Michael B.} and Yasuhito Funahashi",
year = "2013",
month = "1",
doi = "10.1111/j.1442-2042.2012.03226.x",
language = "English",
volume = "20",
pages = "56--63",
journal = "International Journal of Urology",
issn = "0919-8172",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Gene therapy for lower urinary tract dysfunction

AU - Yoshimura, Naoki

AU - Miyazato, Minoru

AU - Sasaki, Katsumi

AU - Yokoyama, Hitoshi

AU - Oguchi, Tomohiko

AU - Chancellor, Michael B.

AU - Funahashi, Yasuhito

PY - 2013/1

Y1 - 2013/1

N2 - Lower urinary tract dysfunction is caused by functional and pathophysiological alterations of the peripheral organs, including the urothelium and detrusor smooth muscle, as well as peripheral and central nervous systems. Recent research in this field has increased our understanding of the mechanisms of lower urinary tract dysfunction, and new drugs have been developed, leading to increased treatment options and changing medical care for lower urinary tract symptoms. Nevertheless, clinicians still often experience refractory and treatment-resistant cases against conventional therapeutic modalities. For such cases, gene therapy targeting for the lower urinary tract and its afferent pathway is anticipated to offer a new therapeutic approach. Therefore, in this article, we review the possibility and current status of gene therapy for lower urinary tract dysfunction.

AB - Lower urinary tract dysfunction is caused by functional and pathophysiological alterations of the peripheral organs, including the urothelium and detrusor smooth muscle, as well as peripheral and central nervous systems. Recent research in this field has increased our understanding of the mechanisms of lower urinary tract dysfunction, and new drugs have been developed, leading to increased treatment options and changing medical care for lower urinary tract symptoms. Nevertheless, clinicians still often experience refractory and treatment-resistant cases against conventional therapeutic modalities. For such cases, gene therapy targeting for the lower urinary tract and its afferent pathway is anticipated to offer a new therapeutic approach. Therefore, in this article, we review the possibility and current status of gene therapy for lower urinary tract dysfunction.

KW - Bladder pain

KW - Gene therapy

KW - Lower urinary tract dysfunction

KW - Overactive bladder

UR - http://www.scopus.com/inward/record.url?scp=84871937980&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84871937980&partnerID=8YFLogxK

U2 - 10.1111/j.1442-2042.2012.03226.x

DO - 10.1111/j.1442-2042.2012.03226.x

M3 - Article

VL - 20

SP - 56

EP - 63

JO - International Journal of Urology

JF - International Journal of Urology

SN - 0919-8172

IS - 1

ER -